Crossmark

Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-018-0386-7

Published Online: 2018-06-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Harrison, John E. http://orcid.org/0000-0002-0225-4923
License Information

Text and Data Mining valid from 2018-06-29
More Information

Article History

First Online: 29 June 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: In the past two years the author has received consultancy fees and honoraria from the following organisations: 23andMe, AbbVie, Access to Quality, Amgen, Anavex, Astellas Pharma, AstraZeneca, Avonex, Avraham, Axon, Axovant, Biogen Idec, Boehringer Ingelheim, Bracket, Cambridge Brain Sciences, Catenion, Cognitive Therapeutics, Compass Pathways Ltd., CRF Health, DeNDRoN, Enzymotec, ePharmaSolutions, Eisai, Eli Lilly, Forum Pharma, Fresh Forward, G4X Discovery, GfHEu, Goetzpartners, Heptares, Janssen AI, Johnson & Johnson, Kaasa Health, Kyowa Hakko Kirin, LivaNova PLC, Lundbeck, MedAvante, Merck, MyCognition, Mind Agilis, Neurocog, Neurim, Neurotrack, Novartis, Nutricia, Orion Pharma, PharmaNet/i3, Pfizer, Prana Biotech, PriceSpective, Probiodrug, Prophase, ProStrakan, Regeneron, Reviva, Roche, Sanofi, Servier, Shire, Takeda, TCG and TransTech Pharma.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.